Spyre Therapeutics Q2 Non-GAAP EPS beats estimates by $0.39

Seeking Alpha··US·Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Spyre Therapeutics reported second-quarter 2026 Non-GAAP earnings per share of negative $0.36, beating analyst expectations by $0.39. As of June 30, 2026, the company held cash, cash equivalents, and marketable securities totaling $1,145.3 million. In April 2026, Spyre raised $435.2 million in net proceeds from a public offering of common stock. Net cash used in operating activities was $69.9 million for the second quarter of 2026.

Impact on assets 1

Biotech & Genomic Medicine▲ · 1 stocks
© 2026 MarketIVNews